"DAVIS Calif. Sept.   PRNewswire  Evolve BioSystems https makers of Evivo httpsevivo.comutm_sourcePRNewswireutm_mediumreferralutm_campaignChromosutm_termMSR baby probiotic today unveiled its prototype for the firstever rapidresponse infant gut microbiome screening test. Using a small stool sample collected from a diaper the test will detect levels of Bifidobacterium a group of beneficial gut bacteria that are especially critical during infancy. The Evivo stool test https will allow doctors to discern whether babies have high or low levels of this key beneficial bacteria Bifidobacterium. Evivos quick and noninvasive test measures the presence of markers that indicate low or high levels of good Bifidobacterium such as acetate and lactate. A stool sample containing high levels of these markers will be strong enough to change the tests liquid display from pink to yellow indicating high levels of Bifidobacterium. The liquid will remain pink if a sample has low levels of acetate and lactate indicating that Bifidobacterium is missing and that key nutrients from breast milk human milk oligosaccharides HMO are being wasted. Evivo has commenced rigorous clinical trials with the prototype to demonstrate the results from infant stool samples. PointofCare Diagnostic Expert Turns Focus to the Infant Gut The development of the prototype is led by Dr. Bethany Henrick Ph.D. Director of Immunology and Diagnostics for Evivo. With more than a decade of experience designing and creating rapid pointofcare diagnostics Henrick was formerly an integral part of the team that developed and optimized the worlds fastest pointofcare HIV test in .   This is the first and only pointofcare screening test designed to identify infants that do not have enough Bifidobacterium levels to create a stable infant gut microbiome said Dr. Henrick. With recent research indicating most babies born after  do not acquire Bifidobacterium at birth our ability to detect significant levels of Bifidobacterium gives pediatricians and parents an immediate indication of whether or not their baby has this beneficial gut bacteria that set them up for lifelong health. Identifying a Disappearing Yet Critical Piece of Gut Health Dr. Henricks previously published findings httpsmsphere.asm.orgcontente which are the basis for the Evivo test show an inverse correlation between rising infant fecal pH reduced acetate and lactate and lower levels of beneficial Bifidobacterium proving that the infant gut microbiome has been rapidly changing over the last three generations. In the past babies acquired Bifidobacterium from their mother during childbirth but due to the increased use of modern medical practices such as antibiotics Csections and formula feeding nine out of  babies born in the U.S. today no longer acquire it. The generational loss of this good bacteria in the infant gut allows for potentially harmful bacteria such as E. Coli and Clostridia to thrive which are linked to higher risk of short and longterm health issues such as colic eczema allergies diabetes and obesity. Currently there is no way to easily determine whether a baby is colonized with healthy bacteria said Mark Underwood M.D. Chief of Neonatology at UC Davis Medical Center. The ability to quickly measure levels of Bifidobacterium in a stool sample would enable pediatricians to identify babies with low levels of these beneficial bacteria and take appropriate action. Evolve BioSystems Evivo is the only baby probiotic clinically proven to restore Bifidobacterium to a babys gut and reduce potentially harmful bacteria by  percent. In a landmark clinical trial httpsmsphere.asm.orgcontente Evivo produced rapid substantial and persistent stabilization of the infant gut microbiome to help set a foundation for lifelong health. About Evolve BioSystems Evolve BioSystems Inc. https is a privatelyheld microbiome company dedicated to developing the next generation of products to establish restore and maintain a healthy gut microbiome. Evolve recently completed a M Series C round of funding coled by the Bill  Melinda Gates Foundation and Horizons Ventures the venture division of the Li Ka Shing Foundation. Evolve is a spinout from the Foods for Health Institute FFHI at the University of California Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components. Having led to the development and commercial launch of products to resolve newborn gut dysbiosis including Evivo https for infants Evolves discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle. In addition to the landmark proofofconcept trial Evolve is undertaking further clinical studies to build out its suite of microbiomebased solutions. SOURCE Evolve BioSystems Inc. Related Links https"